Meningococcal Vaccine

Product Details:

Quadri Meningococcal Polysaccharide Vaccine (e.g., Quadri Meningo™) is an active immunizing agent used to prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y, and W-135. It is administered via a 0.5 mL intramuscular or subcutaneous injection to adults and children (typically >2 years, or >6 months for specific cases) to induce bactericidal antibodies, often used for travellers, military, or outbreak control. Protection lasts for 3 years, with common side effects including injection site reactions, headache, and fever. 

Product Details:

Menactra is a prescription vaccine designed to protect against invasive meningococcal disease caused by serogroups A, C, Y, and W-135. It is administered as an intramuscular injection to individuals between the ages of 9 months and 55 years. The vaccine is important for preventing serious conditions such as meningitis and sepsis and is typically given by a healthcare professional.

Product Details:

Menveo is a vaccine (not a treatment for active infection) approved for active immunization to prevent invasive meningococcal disease (serogroups A, C, Y, and W-135) in individuals aged 2 months to 55 years. It is administered via intramuscular injection, typically in the deltoid muscle.